MYCOVACC
About MYCOVACC
The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre, pan-Canadian study of the long-term impact of myocarditis and pericarditis after mRNA COVID-19 vaccination funded by the Public Health Agency of Canada.
Contact the MYCOVACC Study Team
Email: mycovacc@ccs.ca
Clinical Resources
Listen:
Cardio Connector Podcast Episode – Myocarditis & Pericarditis after mRNA COVID-19 Vaccination: New Clinical Resources
Join Dr. Michael McDonald as he discusses new CCS clinical resources about post-vaccine myocarditis and pericarditis.
Read:
McDonald, M.A., Kafil, T.S, Khoury, M., Luk, A.C., Wright, M.K, & Hawkins, N. M. (2024). Myocarditis and pericarditis following mRNA COVID-19 vaccination: 2024 status and management update. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2024.03.016
Watch:
Myocarditis and Pericarditis after mRNA COVID-19 Vaccination: Status and Management Update (2024)
This CCS continuing professional development webinar provides an update on post-vaccine myocarditis and pericarditis from public health, cardiology, and family medicine perspectives.
Use:
Information for Patients:
Management Algorithm for Health Care Providers:
The updated post-vaccine myocarditis and pericarditis resources were developed in collaboration with the Centre for Evidence-Based Implementation, McMaster University. They are informed by Myocarditis and Pericarditis following mRNA COVID-19 Vaccination: 2024 Status and Management Update in the Canadian Journal of Cardiology. The resources are available in English and French.
News
News Releases
Newsletters
Governance
The MYCOVACC governance structure aims to facilitate the participation and collaboration of CCS members, CCS Affiliate societies, investigators, and patients in study activities.
Steering Committee
The MYCOVACC Steering Committee is chaired by Dr. Nathaniel Hawkins. It includes CCS members as well as representatives from key partner networks and the Public Health Agency of Canada.
Scientific and Data Management Committee
The MYCOVACC Scientific and Data Management Committee ensures high-quality data and ethical data collection, storage, and use. The Committee reviews and makes recommendations to the Steering Committee about all protocols, publications, and reports. The Committee is chaired by Dr. James White and includes CCS members as well as experts from across the scientific community with experience in public health, scientific methodology and data management.
Integrated Knowledge Translation Committee
The MYCOVACC Integrated Knowledge Translation (IKT) Committee develops and supports knowledge translation strategies and activities. The IKT Committee ensures MYCOVACC knowledge products meet the needs of the project’s key stakeholder groups. The Committee is chaired by Dr. Michael McDonald and includes CCS members as well as representatives from across the fields of science and medicine with expertise and experience in knowledge translation and communications. The Committee also consults with patient advisors.
Join the MYCOVACC study
The CCS is actively recruiting cardiac care centres, cardiology clinics and cardiologists from across the country to contribute to this multi-centre study. Study participants will be assessed at three months and 12 months after diagnosis and then annually for up to three years by a participating specialist. They will also be invited to complete quality of life, mental health, physical activity, and health outcomes questionnaires.
Contact the MYCOVACC study team: mycovacc@ccs.ca.
The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.